Sprint Bioscience AB
The answer first
Does Sprint Bioscience beat the market?
Yes, Sprint Bioscience has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 95% of Nordic stocks
- Quality92
- Value46
- Trend96
No. 5 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Sprint Bioscience keeps shrinks about 10% a year for 10 years.
Max for seven days
Follow Sprint Bioscience with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Sprint Bioscience
Your first answer is free, no account needed.
Do you own Sprint Bioscience, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Sprint Bioscience and a few more. Free, no card.
Super Stock+44.6%In short
- Sprint Bioscience has risen 486.8% over the past year, including dividends.
- Overall, Sprint Bioscience ranks better than 95% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 89.5%. The price is 92.4% below its peak now.
What do analysts think of Sprint Bioscience?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 95% of Nordic stocks.
No. 5 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 25 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns1.33
- Return on equityProfit divided by equity+92.1%
- Cash conversionOperating cash flow divided by profit0.97
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 54 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity5.4
- P/SPrice divided by sales3.1
- P/EPrice divided by earnings5.8
- P/CFPrice divided by operating cash flow6.0
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 10 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+23.7%
- 6 months+10.7%
- 9 months+79.8%
- 12 months+486.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Sprint Bioscience
One fund we follow owns Sprint Bioscience. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Sprint Bioscience
Sprint Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 30 employees.
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases.


See the full analysis of Sprint Bioscience.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card